JP2020533958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533958A5 JP2020533958A5 JP2020505240A JP2020505240A JP2020533958A5 JP 2020533958 A5 JP2020533958 A5 JP 2020533958A5 JP 2020505240 A JP2020505240 A JP 2020505240A JP 2020505240 A JP2020505240 A JP 2020505240A JP 2020533958 A5 JP2020533958 A5 JP 2020533958A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- lymphoma
- use according
- cells
- intracellular signaling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000000139 costimulatory effect Effects 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- -1 CD86 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 102100025390 Integrin beta-2 Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102100037904 CD9 antigen Human genes 0.000 claims 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 1
- 101000801227 Homo sapiens Tumor necrosis factor receptor superfamily member 19 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 1
- 102100033760 Tumor necrosis factor receptor superfamily member 19 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023030980A JP7574348B2 (ja) | 2017-07-31 | 2023-03-01 | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 |
| JP2024180515A JP7838050B2 (ja) | 2017-07-31 | 2024-10-16 | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539483P | 2017-07-31 | 2017-07-31 | |
| US62/539,483 | 2017-07-31 | ||
| PCT/US2018/044654 WO2019028051A1 (en) | 2017-07-31 | 2018-07-31 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY ANTI-CD19 / CD20 IMMUNOTHERAPY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030980A Division JP7574348B2 (ja) | 2017-07-31 | 2023-03-01 | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533958A JP2020533958A (ja) | 2020-11-26 |
| JP2020533958A5 true JP2020533958A5 (https=) | 2021-09-09 |
| JP7237926B2 JP7237926B2 (ja) | 2023-03-13 |
Family
ID=63686059
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505240A Active JP7237926B2 (ja) | 2017-07-31 | 2018-07-31 | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 |
| JP2023030980A Active JP7574348B2 (ja) | 2017-07-31 | 2023-03-01 | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 |
| JP2024180515A Active JP7838050B2 (ja) | 2017-07-31 | 2024-10-16 | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023030980A Active JP7574348B2 (ja) | 2017-07-31 | 2023-03-01 | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 |
| JP2024180515A Active JP7838050B2 (ja) | 2017-07-31 | 2024-10-16 | 抗ｃｄ１９／ｃｄ２０免疫療法によりがんを処置するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10442867B2 (https=) |
| EP (1) | EP3661964A1 (https=) |
| JP (3) | JP7237926B2 (https=) |
| CN (1) | CN111183156A (https=) |
| AU (2) | AU2018309735B2 (https=) |
| CA (1) | CA3071624A1 (https=) |
| WO (1) | WO2019028051A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| DK3368571T5 (da) | 2015-10-30 | 2024-09-30 | Univ California | Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| US10442867B2 (en) * | 2017-07-31 | 2019-10-15 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
| CN109423495A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种双靶向嵌合抗原受体及其用途 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN112055717B (zh) | 2018-04-02 | 2024-04-26 | 新加坡国立大学 | 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子 |
| EP3829312A4 (en) * | 2018-08-04 | 2022-07-06 | Abcyte Therapeutics Inc. | MULTIFUNCTIONAL AND MULTI-TARGETING CAR SYSTEM AND METHODS OF USE |
| KR102840400B1 (ko) | 2018-12-12 | 2025-08-04 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| CN109929807A (zh) * | 2018-12-28 | 2019-06-25 | 青岛麦迪赛斯生物科技有限公司 | 一种靶向血液肿瘤的双嵌合抗原受体修饰的t淋巴细胞 |
| US20220133791A1 (en) * | 2019-01-23 | 2022-05-05 | Miltenyi Biotec B.V. & Co. KG | A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subject |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN113924103B (zh) * | 2019-03-06 | 2025-02-14 | 莱蒂恩技术公司 | 用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法 |
| CN111825769B (zh) * | 2019-04-16 | 2022-03-25 | 上海科技大学 | 一种泛素化缺失的嵌合抗原受体及其用途 |
| MX2021015967A (es) * | 2019-06-27 | 2022-04-06 | Eutilex Co Ltd | Receptor de antigeno quimerico con dominio coestimulador 4-1bb. |
| CN112390891B (zh) * | 2019-08-14 | 2022-06-03 | 苏州方德门达新药开发有限公司 | 嵌合抗原受体及其构建方法和应用 |
| EP4028417A4 (en) * | 2019-09-13 | 2024-01-24 | Admare Therapeutics Society | ANTI-ONCOLYTIC VIRUS ANTIGEN ANTIBODIES AND METHOD OF USE THEREOF |
| CN112079934B (zh) * | 2019-12-17 | 2021-01-29 | 合源生物科技(天津)有限公司 | 一种靶向cd19的嵌合抗原受体及其用途 |
| CN110981971B (zh) * | 2019-12-25 | 2022-12-16 | 华夏源（上海）细胞基因工程股份有限公司 | 一种靶向cd19和cd20的双靶点嵌合抗原受体及其表达载体和应用 |
| CA3167572A1 (en) * | 2020-02-14 | 2021-08-19 | Robbie G. MAJZNER | Chimeric antigen receptors with cd2 activation |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN113549155B (zh) * | 2020-04-23 | 2023-03-31 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 同时靶向cd19和cd20的嵌合抗原受体及其应用 |
| WO2021262723A1 (en) * | 2020-06-22 | 2021-12-30 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| KR102393776B1 (ko) * | 2020-12-30 | 2022-05-04 | (주)이노베이션바이오 | Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체 |
| CA3209218A1 (en) * | 2021-01-27 | 2022-08-04 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Bi-specific car t cells for b cell malignancies |
| EP4384549A1 (en) * | 2021-08-12 | 2024-06-19 | Cellogen Therapeutics Pvt. Ltd. | Chimeric antigen receptors (car) for b cell malignancies |
| TW202334400A (zh) | 2021-12-30 | 2023-09-01 | 美商Ｔｒ１Ｘ股份有限公司 | 表現il-10及嵌合抗原受體之cd4+ t細胞及其用途 |
| WO2024173607A2 (en) * | 2023-02-14 | 2024-08-22 | Evolveimmune Therapeutics, Inc. | Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment |
| KR20260005874A (ko) | 2023-02-28 | 2026-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 전신 자가면역 질환을 치료하기 위한 세포 요법 |
| WO2024192134A1 (en) * | 2023-03-13 | 2024-09-19 | Immpact Bio Usa, Inc. | Bispecific cars for the treatment of lupus and autoimmune diseases |
| CA3278900A1 (en) | 2023-03-31 | 2024-10-03 | AbelZeta Inc. | BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA |
| CN119522238A (zh) * | 2023-05-19 | 2025-02-25 | 恺兴生命科技(上海)有限公司 | 免疫效应细胞及其应用 |
| WO2025006895A1 (en) * | 2023-06-28 | 2025-01-02 | Saliogen Therapeutics Inc. | Nucleic acid constructs and engineered cells for allogeneic therapies |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025231185A1 (en) | 2024-05-01 | 2025-11-06 | Legend Biotech Ireland Limited | Viral glycoprotein variants and uses thereof |
| WO2025246739A1 (zh) * | 2024-05-29 | 2025-12-04 | 深圳豪石生物科技有限公司 | 人源化cd20抗体及其相关产品和应用 |
| CN120248134B (zh) * | 2025-03-31 | 2025-12-23 | 深圳大学总医院 | 一种CD19 CD20 CAR/TRuC-T细胞及其相关产品和应用 |
| WO2026015450A1 (en) | 2024-07-06 | 2026-01-15 | Tr1X, Inc. | Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof |
| WO2026050426A2 (en) | 2024-08-28 | 2026-03-05 | Juno Therapeutics, Inc. | Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
| US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Acylhydrazone derivatives of anthracycline and methods for their preparation |
| US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
| US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
| US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| AU668384B2 (en) | 1992-03-12 | 1996-05-02 | Alkermes Controlled Therapeutics, Inc. | Controlled release ACTH containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
| US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
| US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
| US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| ATE234635T1 (de) | 1995-12-22 | 2003-04-15 | Bristol Myers Squibb Co | Verzweigte hydrazongruppen enthaltende kuppler |
| DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| WO2001058479A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| US20050113564A1 (en) | 2003-11-05 | 2005-05-26 | St. Jude Children's Research Hospital | Chimeric receptors with 4-1BB stimulatory signaling domain |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| WO2011038159A2 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
| WO2011106723A2 (en) | 2010-02-26 | 2011-09-01 | Lpath, Inc. | Anti-paf antibodies |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| US11041021B2 (en) * | 2014-05-23 | 2021-06-22 | University Of Florida Research Foundation, Incorporated | Car based immunotherapy |
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| WO2017027291A1 (en) * | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| JP7114490B2 (ja) | 2016-06-24 | 2022-08-08 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| EP4282969A3 (en) * | 2016-09-02 | 2024-01-31 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| US10442867B2 (en) | 2017-07-31 | 2019-10-15 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
-
2018
- 2018-07-31 US US16/050,754 patent/US10442867B2/en active Active
- 2018-07-31 CN CN201880063737.4A patent/CN111183156A/zh active Pending
- 2018-07-31 EP EP18779075.3A patent/EP3661964A1/en active Pending
- 2018-07-31 JP JP2020505240A patent/JP7237926B2/ja active Active
- 2018-07-31 WO PCT/US2018/044654 patent/WO2019028051A1/en not_active Ceased
- 2018-07-31 CA CA3071624A patent/CA3071624A1/en active Pending
- 2018-07-31 AU AU2018309735A patent/AU2018309735B2/en active Active
-
2019
- 2019-10-11 US US16/599,473 patent/US11680103B2/en active Active
-
2023
- 2023-03-01 JP JP2023030980A patent/JP7574348B2/ja active Active
- 2023-05-04 US US18/312,112 patent/US20240034802A1/en active Pending
-
2024
- 2024-10-16 JP JP2024180515A patent/JP7838050B2/ja active Active
-
2025
- 2025-05-29 AU AU2025204005A patent/AU2025204005A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533958A5 (https=) | ||
| JP2021500881A5 (https=) | ||
| JP2022501043A5 (https=) | ||
| JP2020513829A5 (https=) | ||
| JP2022502043A5 (https=) | ||
| JP2020517295A5 (https=) | ||
| JPWO2020061498A5 (https=) | ||
| JP2025032091A5 (https=) | ||
| JP2018535701A5 (https=) | ||
| JP2017524367A5 (https=) | ||
| JP2020114264A5 (https=) | ||
| JP2025028239A5 (https=) | ||
| JP2021094037A5 (https=) | ||
| JP2018527014A5 (https=) | ||
| JP2021524264A5 (https=) | ||
| HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
| JP2019523301A5 (https=) | ||
| JP2018525033A5 (https=) | ||
| JP2016514457A5 (https=) | ||
| RU2020117196A (ru) | Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей | |
| JP2020513754A5 (https=) | ||
| JP2016514462A5 (https=) | ||
| JPWO2020069184A5 (https=) | ||
| JPWO2020228825A5 (https=) | ||
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |